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S U M M A R Y
Dasatinib may cause various adverse effects such as myelosuppression and pleural effusion. It is well
known that dasatinib may affect cellular immunity, which leads to the subsequent risk of a myriad of
infections and viral reactivations, especially cytomegalovirus. Pneumocystis jiroveci pneumonia (PJP) is
an opportunistic infection that typically occurs in immunocompromised hosts. Although pneumonia is
not uncommon among dasatinib-treated patients, dasatinib-associated PJP has been reported only once
in the literature, without a description of the clinical details. We report herein two cases of PJP in patients
receiving treatment containing dasatinib. One patient developed PJP at 7 months following dasatinib in
combination with chemotherapy for the treatment of acute lymphoblastic leukemia. The other patient
developed pleural effusion and PJP at 2 years following dasatinib treatment for chronic myeloid
leukemia. Both patients recovered well after management with sulfamethoxazole/trimethoprim. Our
experience illustrates that PJP is a potentially important complication of dasatinib-based treatment.
Raising clinical awareness is important as prompt diagnosis and timely management are the
cornerstones of successful treatment.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Dasatinib is a potent tyrosine kinase inhibitor used in the
treatment of chronic myeloid leukemia (CML) and Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Dasatinib may cause both myelosuppression and immunosup-
pression. Therefore, various types of infection, including those
caused by bacteria, viruses, and fungi, may occur in patients
receiving dasatinib treatment.1 Pneumocystis jiroveci pneumonia
(PJP) has been reported only once in patients taking dasatinib,
without a description of the clinical details.2 We encountered two
cases of PJP following dasatinib treatment. The possible mecha-
nism and clinical importance are discussed.
2. Case reports
2.1. Case 1
A 30-year-old female was diagnosed with Ph+ ALL in February
2012. She received chemotherapy in accordance with the* Corresponding author. Tel.: +886 3 3281200 ext. 2524; fax: +886 3 3286697.
E-mail address: doctor.horngchang@gmail.com (H. Chang).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).hyper-CVAD (cyclophosphamide, vincristine, Adriamycin, and
dexamethasone) regimen. Imatinib 600 mg per day was added
to the treatment course, which was changed to dasatinib 140 mg
per day 7 months later due to a loss of molecular response. She had
cytomegalovirus (CMV) antigenemia during dasatinib treatment.
Valganciclovir 450 mg twice daily was prescribed. She completed
the entire hyper-CVAD treatment course, which was followed by
maintenance therapy based on methotrexate, vincristine, mercap-
topurine, and prednisolone. Seven months after initiating dasatinib
treatment, she had fever and rapidly progressive dyspnea. Ten days
prior to admission, she had received methotrexate 20 mg/m2 and
6-mercaptopurine 150 mg per day for a week. Her white blood cell
count was 0.3  109/l (36% lymphocytes). A chest radiograph
revealed diffuse pulmonary inﬁltration. She was intubated and
admitted to an intensive care unit. Empirical antibiotic treatment
with sulfamethoxazole/trimethoprim, piperacillin/tazobactam,
and vancomycin was administered. PJP was detected in the
sputum sample by PCR assay. Therefore, sulfamethoxazole/
trimethoprim was used for a total of 28 days. During the treatment
period, various microbiology surveys were done. All blood cultures
(six sets) were sterile. All sputum cultures (three sets) and a urine
culture yielded no speciﬁc offending microorganisms. No virus was
identiﬁed by sputum viral culture. Blood CMV antigen wasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Patient 1: This Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patient developed fever and dyspnea after 2 years of dasatinib treatment
and chemotherapy prior to admission. Various septic workups were done. Pneumocystis jiroveci pneumonia (PJP) was the only yield in the microbiology studies. The temporal
sequence of dasatinib, chemotherapy, antibiotics, and sulfamethoxazole/trimethoprim is shown.
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admission, but no CMV antigenemia was detected after admission.
Urine was negative for Legionella antigen and serum was negative
for Aspergillus galactomannan antigen detection. The patient’s
clinical course is summarized in Figure 1. Her dyspnea and
pulmonary inﬁltrates improved after treatment. She was weaned
from the ventilator and discharged in a stable condition.
Subsequent dasatinib treatment was resumed. She continued to
experience occasional CMV antigenemia, which was treated
preemptively with valganciclovir 450 mg twice daily. At the time
of writing, the patient has experienced no further febrile episodes
or pneumonia.
2.2. Case 2
A 55-year-old male patient had CML, in the chronic phase. The
diagnosis was made in 2008 and he had received imatinib 400 mg
per day for treatment. Due to a loss of molecular response, theFigure 2. Patient 2: This chronic myeloid leukemia (CML) patient developed recurre
furosemide, and dasatinib withdrawal is shown. The patient was treated with sulfam
treatment.treatment was changed to dasatinib 100 mg per day in 2010. He
developed a left-side pleural effusion after 2 years of dasatinib
treatment. The effusion comprised lymphocyte-predominant
exudates. Results of cytology and microbiology studies were
negative. Dasatinib was withdrawn temporarily. The effusion
resolved after management with dexamethasone (8 mg per day for
14 days) and diuretics. Dasatinib was resumed after 23 days. Two
weeks later, he had recurrence of the left-side pleural effusion.
Dasatinib was discontinued and dexamethasone (8 mg per day for
14 days then 4 mg per day for another 14 days) and diuretics were
given again for treatment. The effusion resolved. Two months after
complete discontinuation of dasatinib, he had a second recurrence
of the pleural effusion along with bilateral lower lung inﬁltrations.
A high-resolution lung scan revealed scattered interstitial inﬁltra-
tion with ground glass opacities in the right lower lung.
Bronchoscopy and bronchoalveolar lavage were done. While all
cytology and microbiology ﬁndings were unremarkable, PJP was
detected by PCR assay in the lavage sample. He was treated withnt pleural effusion after dasatinib treatment. The temporal sequence of steroids,
ethoxazole/trimethoprim and dasatinib and was switched to nilotinib for CML
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effusion regressed.
Due to the recurrent pleural effusion and suboptimal molecular
response, the patient’s treatment for CML was subsequently
changed to nilotinib 800 mg per day. He has been doing well.
Neither the effusion nor pulmonary inﬁltrates has since recurred.
The patient’s clinical treatment is summarized in Figure 2.
3. Discussion
Dasatinib is a multi-kinase inhibitor that is used mainly in the
treatment of CML and Ph+ ALL. The immunomodulatory effects of
dasatinib are well known. Patients receiving dasatinib treatment
may have a rapid response of increased large granular lympho-
cytes. Such an increase in the lymphocyte subpopulation is
associated with a superior treatment response for CML and Ph+
ALL. Further studies have revealed that the expanded lymphocyte
subpopulation consists of natural killer (NK) cells and cytotoxic T
cells. An increase in blood B cells has also been reported. However,
the impact on immune function of such altered cell numbers is not
entirely understood. Although the number of NK cells is increased,
most studies have found the cytotoxicity of the NK cells to be
decreased.3 Another cell colony commonly affected by dasatinib is
cytotoxic T cells. Cytotoxic T cells with CD8 expression have been
reported to be signiﬁcantly increased in some published studies.4,5
Our understanding of the functional effects of such an increase in
cytotoxic T cells is limited. Sillaber et al. reported suppression of T-
cell receptor -dependent activation of T-lymphocytes, suggesting
that the function of CD8-expressing T cells was compromised.2
Despite the increase in lymphocyte counts, it is well known that
dasatinib has immunosuppressive effects. Various infections may
occur among patients receiving dasatinib treatment. Rodriguez
et al. investigated a single institute cohort in which 69 patients
received dasatinib treatment for CML or Ph+ ALL. Bacteria were the
most common offending microorganisms and pneumonia was the
most common type of infection associated with dasatinib. Both
Gram-positive and Gram-negative bacteria, along with Clostridium
difﬁcile colitis, were reported. Virus infections occurred in only four
patients (7%) and only one patient had CMV colitis. No patient had
PJP in their series, although pneumonia accounted for 23% of all
infection episodes.1 In that study, half of the infection episodes
occurred during neutropenia. It is not surprising that infection
events are predominantly of bacterial origin. In other reports,
however, dasatinib has often been associated with opportunistic
infections. The most commonly reported such infection associated
with dasatinib is probably CMV reactivation,4 particularly CMV
colitis. In contrast to CMV reactivation, PJP has been reported onlyonce in the literature to our knowledge. In a safety proﬁle analysis
of patients taking dasatinib 140 mg per day by Sillaber et al., the
most common side effects were body weight loss (6/16 patients),
pleural effusions (12/16), and infectious complications (12/16).
Among all those with infectious complications, one patient died
from PJP.2
In the present study, two patients developed PJP after receiving
dasatinib for relatively long treatment periods (7 months and 2
years, respectively). In addition to PJP, both patients had other
complications, including one with CMV reactivation and the other
with pleural effusion. This illustrates that different side effects of
dasatinib may occur in the same patient, probably due to its potent
drug effects. Furthermore, patient 1 received chemotherapy and
steroids in combination with dasatinib. Patient 2 received
dexamethasone for the management of pleural effusion. Both
chemotherapy and steroids may add to the increased risk of
opportunistic infections associated with dasatinib. In addition to
dasatinib, we cannot rule out the possibility that leukemia per se
may lead to susceptibility to opportunistic infections. However,
both our patients developed PJP during remission and not at the
time of initial diagnosis of leukemia. In our literature search, no
case of PJP has been reported upon manifestation of CML or Ph+
ALL, which suggests that PJP is more closely related to dasatinib
than leukemia. Our experience suggests that PJP should be kept in
mind when dealing with patients on dasatinib treatment,
especially when it is used in combination with steroids or
chemotherapy.
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